Our demonstration that compensation for CHCHD6 deficiency mitigates AD-associated neuropathology and cognitive impairment suggests that stabilization of the CHCHD6–APP axis represents a novel therapeutic target for AD patients. This evidence concerns the gene CHCHD6 and Cognitive impairment.